Pfizer, Inc. · NYSE:PFE
Pfizer — Citi 2016 Global Healthcare Conference
8 slides from Pfizer's conference presentation, Dec 8, 2016
Slide 1: Citi 2016 Global Healthcare Conference
Citi 2016 Global Healthcare Conference Mikael Dolsten, M.D., Ph.D. President Pfizer Worldwide R&D December 8th, 2016
Slide 2: Forward-looking Statements
Forward-looking Statements • This presentation includes forward-looking statements about, among other things, development of Pfizer’s products and product candidates, including their potential benefits, expected clinical trial study starts and expected regulatory submissions and approvals that are s
Slide 3: Strong Track Record of Approvals
Strong Track Record of Approvals Over the last 6 years >30 Phase 3 starts & >15 key approvals (10 NME’s) Crisaborole* (*PDUFA 2017) (Adult / CAPiTA) Robust Pipeline Positioned for Sustainable Productivity ~50% biologics, biosimilars and vaccines 214 Discovery Discovery Phase 1 Phase 2 Phase 3 Regist
Slide 4: Key Regulatory News Flow
2016 A Productive Year for Pfizer R&D Key Regulatory News Flow APPROVALS Adv. BC (EU) ROS+ NSCLC QD MR Infant Rec. Adv. BC (US/EU) (US/EU) (US) (CN) SUBMISSIONS Antibody Drug Conjugates Immuno Oncology Cardiovascular inotuzumab Mylotarg avelumab ertugliflozin ALL AML Merkel Cell T2D (US1/EU) (US/EU1
Slide 5: Key Clinical News Flow
2016 A Productive Year for Pfizer R&D Key Clinical News Flow DATA READ OUTS BACE, GSM C. Difficile ertugliflozin Alzheimer's Vaccine Diabetes Tyk2/JAK1 glasdegib tofacitinib Psoriasis Leukemia UC & PsA PHASE 1 PHASE 2 PHASE 3 STUDY STARTS P-cadherin Bi Fx JAK1 avelumab Mono Cancer Atopic Dermatitis
Slide 6: 2016 A Productive Year for Pfizer R&D
2016 A Productive Year for Pfizer R&D Leveraging the External Environment EXTERNAL FOCUS AREAS SELECT 2016 ACTIVITIES Strengthen pipelines with highly differentiated, quality assets Enable Strategic Focus Areas via “Build & Buy” (GTx, I/O) Access novel targets & breakthrough platforms For presentati
Slide 7: Delivering the Next Wave of Innovation
Delivering the Next Wave of Innovation (Potential Clinical Milestones by 2018) ONCOLOGY RARE DISEASE I&I Up to 10 Triplets & Doublets 3 Gene Therapy Assets ~10 Ph 2 Selective Kinases Cancer Vaccine Triplet Hemophilia B JAK1 avelumab+41BB+OX40 DMD JAK3 avelumab+41BB+IDO Friedrich’s Ataxia TYK2/JAK1 a
Slide 8: Q&A
Q&A